Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients

Sponsor
International Medical University (Other)
Overall Status
Completed
CT.gov ID
NCT04400552
Collaborator
Kotra Pharma (M) Sdn Bhd (Other)
91
1
3
30.1
3

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery.

The hypothesis is pre-operative ONS feeding in malnourished surgical cancer patients is effective on improving nutritional status. An extended period of 3 months post-operative ONS feeding is effective on improving nutritional status as compared to ONS feeding post-operatively during hospital stay only. Perioperative feeding is effective on improving secondary outcomes such as sleep quality, post-operative complications and length of hospital stay.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: ONS Pre-op + ONS Post-op
  • Dietary Supplement: ONS Pre-op + ONS Post-op + ONS Post-op 3 months
  • Dietary Supplement: Usual intake Pre-op + ONS Post-op
N/A

Detailed Description

The main objective of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery.

The specific objectives are:
  1. To evaluate the baseline nutritional status of cancer patients undergoing elective surgery

  2. To evaluate the effectiveness of pre-operative ONS feeding on nutritional status in malnourished surgical cancer patients

  3. To evaluate the effectiveness of an extended 3 months post-operative ONS feeding after discharge versus ONS feeding only post-operatively during hospital on nutritional status

  4. To evaluate secondary outcomes of perioperative feeding such as sleep quality, post-operative complications and length of hospital stay

Study Design: This is a randomised-controlled-open label-parallel group(s)-trial which will be conducted on malnourished cancer patients undergoing elective surgery.

Study duration: The participation duration for each participant is 4 months. The completion of the study will take around 30 months.

Study Design

Study Type:
Interventional
Actual Enrollment :
91 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients- A Randomized Controlled Trial
Actual Study Start Date :
Dec 26, 2018
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: ONS Pre-op + ONS Post-op

Oral nutrition supplementation (ONS) pre-operatively and post-operatively up to being discharged from hospital

Dietary Supplement: ONS Pre-op + ONS Post-op
Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.

Active Comparator: ONS Pre-op + ONS Post-op + ONS Post-op 3 months

Oral nutrition supplementation (ONS) pre-operatively, post-operatively up to being discharged from hospital and an extended oral nutrition supplementation post-operatively up to 3 months

Dietary Supplement: ONS Pre-op + ONS Post-op + ONS Post-op 3 months
Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.

Active Comparator: Usual intake Pre-op + ONS Post-op

Follow a meal plan of 2000 kcal / day using conventional foods and oral nutrition supplementation (ONS) post-operatively up to being discharged from hospital

Dietary Supplement: Usual intake Pre-op + ONS Post-op
Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital

Outcome Measures

Primary Outcome Measures

  1. Change in body weight [Change from baseline body weight at 4 months]

    Anthropometry measurement

  2. Change in body mass index (BMI) [Change from baseline body mass index (BMI) at 4 months]

    Anthropometry measurement

  3. Change in serum albumin level [Change from baseline serum albumin level at 4 months]

    Serum albumin is an indicator of protein stores to assess nutritional status

  4. Change in serum pre-albumin level [Change from baseline serum pre-albumin level at 4 months]

    Serum pre-albumin is an indicator of protein stores to assess nutritional status

Secondary Outcome Measures

  1. Change in handgrip force [Change from baseline handgrip force at 4 months]

    Handgrip force is a measure of handgrip strength by dynamometer

  2. Change in muscle mass [Change from baseline muscle mass at 4 months]

    Muscle mass reported in kilogram is measured by bioelectrical impedance analyser

  3. Change in fat mass [Change from baseline fat mass at 4 months]

    Fat mass reported in kilogram is measured by bioelectrical impedance analyser

  4. Change in serum transferrin level [Change from baseline serum transferrin level at 4 months]

    Serum transferrin is a measure of nutritional status

  5. Change in hemoglobin level [Change from baseline hemoglobin level at 4 months]

    Serum hemoglobin is a measure of nutritional status

  6. Change in high sensitivity c-reactive protein (HsCRP) level [Change from baseline high sensitivity c-reactive protein (HsCRP) level at 4 months]

    High sensitivity c-reactive protein (HsCRP) is a measure of inflammatory status

  7. Change in Interleukin-6 (IL-6) [Change from baseline Interleukin-6 (IL-6) at 4 months]

    Interleukin-6 (IL-6) is a measure of inflammatory status

  8. Change in salivary cortisol level [Change from baseline salivary cortisol level at 4 months]

    Salivary cortisol level is a biological marker of stress reaction

  9. Change in energy intake [Change from baseline energy intake at 4 months]

    Energy intake reported in calories is a dietary measure to assess nutritional status

  10. Change in protein intake [Change from baseline protein intake at 4 months]

    Protein intake reported in gram is a dietary measure to assess nutritional status

  11. Change in Pittsburgh Sleep Quality Index (PSQI) scores [Change from baseline Pittsburgh Sleep Quality Index (PSQI) scores at 4 months]

    Pittsburgh Sleep Quality Index (PSQI) scores range from 0-42.Higher scores indicate poorer sleep quality

  12. Presence of post-surgical complications [Change from baseline post-surgical complications at 3 months]

    Post-surgical complications are indicated by presence of wound infection, chest infection and use of antibiotics, responses are either yes or no

  13. Length of hospital stay [Up to 5 days]

    Number of days participants are admitted into the hospital

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female from all ethnicity

  • 25 to 65 years

  • BMI not less than 18.0 kg/m²

  • Cancer patients who are confirmed with elective surgery whose co-morbidities are stabilized based on the ASA Physical Status Classification System ASA Class 1 and 2

  • Fulfil at least two characteristics of AND/ ASPEN Diagnosis of Malnutrition These characteristics are insufficient energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, localized or generalized fluid accumulation and diminished functional status as measured by handgrip strength.

Exclusion Criteria:
  • Patients who require enteral or parenteral feeding

  • Pregnant or lactating

  • On chemotherapy or radiotherapy

  • Total gastrectomy or ileostomy

  • Metastasized cancer, upper gastrointestinal cancer, terminal diseases, decompensated liver or renal disease, major concurrent metabolic problem such as uncontrolled diabetes, dementia

  • On regular steroids prescription

Contacts and Locations

Locations

Site City State Country Postal Code
1 International Medical University Kuala Lumpur Malaysia 57000

Sponsors and Collaborators

  • International Medical University
  • Kotra Pharma (M) Sdn Bhd

Investigators

  • Principal Investigator: Winnie SS Chee, PhD, International Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Winnie Chee, Principal Investigator, International Medical University
ClinicalTrials.gov Identifier:
NCT04400552
Other Study ID Numbers:
  • IMU R204/2017
First Posted:
May 22, 2020
Last Update Posted:
Aug 25, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2021